#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Li et al.

01-08-05

Docket No.:

275.0003 0102

IC951eu.s. PTO COMPOSITION AND METHOD FOR IN VIVO AND IN VITRO ATTENUATION OF GENE EXPRESSION



1/04/02 ssistant Commissioner for Patents

ATTN: Box PATENT APPLICATION

Washington, D.C. 20231

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

- X Copy of UTILITY PATENT APPLICATION including:
  - X Specification (46 consecutively numbered pgs, including 61 claims on 8 pgs, and a 1pg Abstract);
  - X Drawings (13 Figures on 9 sheets);
  - X A copy of a signed Declaration and Power of Attorney (8 pgs).
- X Application Data Sheet (4 pgs).
- X An itemized return postcard.
- X Preliminary Amendment (3 pgs, including Appendix (1 pg)).
- X Communication Requesting Entry of Sequence Listing (2 pgs), Computer readable form of "Sequence Listing" (one disk) and paper copy of "Sequence Listing" (8 pgs). Applicants state that the paper copy form of the "Sequence Listing" section of the present application, and the computer readable form submitted herewith, are the same.
- X Other: Request for Filing a Continuation Application Under Rule § 1.53(b) (3 pgs).
- X Please charge Deposit Account No. 13-4895 in the amount of \$991 for the application filing fee, which is calculated below:

# <u>X</u>

### Small Entity Status is entitled to be asserted in the above-identified application.

APPLICATION FILING FEE					
	Number of Pending Claims (1)	Claims Included in Basic Filing Fee (2)	Number of Extra Claims (1-2)	Cost per Extra Claim	
Total Claims	61	20	41	x \$9 =	369
Independent Claims	9	3	6	x \$42 =	252
One or More Multiple Dependent Claims Presented? If Yes, Enter \$140 Here →					0
Enter Basic Filing Fee (Utility Patent \$370) Here →					370
			Total App	lication Filing Fee	991

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

MULEURING	T) A	ACCIT	0_	GEBHARDT	א מ
MUBLING.	KA	ANCH	X.	GEBHARDI	РΑ

Customer Number: 26813

Name: David L. Provence

Reg. No.: 43,022

By:

Direct Dial: 612-305-1006 Facsimile: 612-305-1228

CERTIFICA	TF.	LINDER	27	CED	81	10
CENTIFICA	$\mathbf{L}$	UNDER	$\mathcal{I}$	CFK	QI.	. IU

"Express Mail" mailing label number: EL 888274043 US

Date of Deposit: <u>January 4, 2002</u>

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Attn: Box PATENT APPLICATION, Washington, D.C. 20231.

By: Yor John Name: Gara Ladwig

(SMALL ENTITY TRANSMITTAL UNDER RULE 1.10)



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket Number	Anticipated Classif	ication	Prior Application	7
275.0003 0102	Class	Subclass	Examiner J. Kerr	Art Unit 1633

# REQUEST FOR FILING A CONTINUATION APPLICATION UNDER RULE §1.53(b)

Assistant Commissioner for Patents Attn: Box PATENT APPLICATION

Washington, D.C. 20231

Sir:

This is a request for filing a continuation application under 37 CFR §1.53(b) of Serial No. 09/493,301, Confirmation No. 2058 filed on January 28, 2000, entitled COMPOSITION AND METHOD FOR IN VIVO AND IN VITRO ATTENUATION OF GENE EXPRESSION USING DOUBLE STRANDED RNA, which claims priority to U.S. Serial No. 60/117,635 filed on January 28, 1999, entitled DOUBLE STRANDED RNA BLOCKS SPECIFIC GENE EXPRESSION IN MULTICELLLAR SETTINGS IN IN VIVO AND IN VITRO, and U.S. Serial No. 60/175,440 filed on January 11, 2000, entitled DOUBLE STRANDED RNA BLOCKS SPECIFIC GENE EXPRESSION IN MULTICELLLAR SETTINGS IN IN VIVO AND IN VITRO, by the following inventors (name, address, and citizenship):

Yin-Xiong Li

816 Marilee Glen Court Durham, NC 27705

Citizenship: People's Republic of China

Michael J. Farrell 7043 Laramie Avenue Canoga Park, CA 91306 Citizenship: U.S.A.

Margaret L. Kirby 223 Fleming Drive Durham, NC 27712 Citizenship: U.S.A.

- 1. X Enclosed is a copy of the specification (including claims, abstract, and drawings) as filed in the prior application.
- 2. \_\_ Enclosed is a new specification (including claims and abstract). The entire disclosure of the prior

Request for Filing a Continuation Application Under Rule §1.53(b)

Filed: ON EVEN DATE HEREWITH

Title: COMPOSITION AND METHOD FOR IN VIVO AND IN VITRO ATTENUATION OF GENE EXPRESSION USING

DOUBLE STRANDED RNA

application is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference.

- Enclosed is a copy of the Declaration and Power of Attorney filed in the prior application.  $\mathbf{X}$
- Enclosed is a newly executed Declaration and Power of Attorney. 4.
- Enclosed are drawings (\_\_\_ sheets). 5.
- Cancel in this application claims \_\_\_\_ before calculating the filing fee. (At least one independent claim must be retained for filing purposes.)
  - A preliminary amendment is enclosed. <u>X</u>
  - The filing fee is calculated below: X

		CLAIMS AS FILE	Ď	
NUMBER FILED		NUMBER EXTRA	RATE	BASIC FEE \$370
Total Claims	61-20 =	41	\$9	\$369
Independent Claims	9-3 =	6	\$42	\$252
MULTIPLE DEPENI	DENT CLAIM	PRESENTED	\$140	\$0
			FILING FEE:	\$991

- The Commissioner is hereby authorized to charge the application filing fee in the amount of \$991 to  $\mathbf{X}_{\cdot}$ 9. Account No. 13-4895.
- The Commissioner is hereby authorized to charge any additional fees as set forth in 37 CFR §1.16 10. <u>X</u> to 1.18 which may be required by this paper or credit any overpayment to Account No. 13-4895.
- This application is being filed by less than all of the inventors named in the prior application. Please 11. \_ delete the names of the following inventor(s) who are not inventors of the invention claimed in the present application:
- Amend the specification by inserting as the first sentence on page 1, the following: -- This is a 12. continuation of application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, (pending/issued/abandoned), which is incorporated herein by reference.--

<ul> <li>13 Priority of foreign application Serial No, filed on in (country) is claimed under U.S.C. §119.</li> <li>14. X The prior application is assigned of record to Medical College of Georgia Research Institute,</li> </ul>	
U.S.C. §119.	
14. X The prior application is assigned of record to Medical College of Georgia Research Institute,	e, Inc
15. $\underline{X}$ The Power of Attorney in the prior application is to:	
Victoria A. Sandberg  Mueting, Raasch & Gebhardt, P.A.  P.O. Box 581415  Minneapolis, MN 55458-1415  Customer Number 26813  X Small Entity Status is entitled to be asserted in the above-identified application.  Address all future communications to:	
MUETING, RAASCH & GEBHARDT, P.A. P.O. Box 581415 Minneapolis, Minnesota 55458-1415 Customer Number 26813 Attn: David L. Provence	
Attn: David L. Provence (Telephone: 612-305-1220) (Facsimile: 612-305-1228)  Date: David L. Provence	

Reg. No. 43,022

Direct Dial (612) 305-1005

"Express Mail" mailing label number EL 888274043 US

Date of Deposit <u>January 4, 2002</u>

I hereby certify that this paper and/or fee is/are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Attn: Box PATENT APPLICATION, Washington,

D. C. 20231.

Name: Gara Ladwig

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Li et al.	) Group Art Unit:	1633
Serial No.:	Unassigned (Parent: 09/493,301)	) ) Examiner:	(prior application)  J. Kerr
	(	)	(prior application)
Filed:	Herewith (Parent: January 28, 2000)	)	
For:	COMPOSITION AND MET ATTENUATION OF GENE RNA		

# COMMUNICATION REQUESTING ENTRY OF SEQUENCE LISTING

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §1.821 et seq., a computer readable form (CRF) and written Sequence Listing for the above-captioned application are submitted herewith. Applicants request entry of same into the specification.

In accordance with 37 C.F.R. §1.821 et seq., it is respectfully submitted that the written Sequence Listing and the Computer readable form of the Sequence Listing are identical. It is further submitted that Sequence Listing does not contain new matter.

## Communication Requesting Entry of Sequence Listing

Serial No.: Unknown Confirmation No.: Unknown

Filed: HEREWITH

For: COMPOSITION AND METHOD FOR IN VIVO AND IN VITRO ATTENUATION OF GENE EXPRESSION

USING DOUBLE STRANDED RNA

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number if prosecution of this application may be assisted thereby.

Respectfully submitted for

Li et al.

By Mueting, Raasch & Gebhardt, P.A.

Minneapolis, MN 55458-1415

Phone: (612)305-1220 Facsimile: (612)305-1228 **Customer Number 26813** 

P.O. Box 581415

January 4, 2002

Date

David L. Provence Reg. No. 43,022

Direct Dial (612) 305-1005

enema

"Express Mail" mailing label number EL 888274043 US

Date of Deposit January 4, 2002

I hereby certify that this paper and/or fee is/are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Attn: Box PATENT

APPLICATION, Washington, D. C. 20231/

Name: Gara Ladwig